Peapack Gladstone Financial Corp Has $3.67 Million Holdings in Zoetis Inc. $ZTS

Peapack Gladstone Financial Corp lessened its stake in Zoetis Inc. (NYSE:ZTS) by 60.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,173 shares of the company’s stock after selling 44,429 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Zoetis were worth $3,671,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. Geode Capital Management LLC increased its position in Zoetis by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock valued at $1,420,294,000 after acquiring an additional 189,235 shares in the last quarter. Norges Bank acquired a new stake in Zoetis in the 4th quarter valued at about $734,425,000. Nordea Investment Management AB increased its position in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after buying an additional 550,859 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 1.5%

Shares of NYSE ZTS opened at $76.42 on Wednesday. The stock has a market cap of $32.04 billion, a P/E ratio of 12.67, a P/E/G ratio of 1.27 and a beta of 0.75. The firm has a 50 day moving average price of $103.52 and a 200 day moving average price of $116.71. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts expect that Zoetis Inc. will post 6.89 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s payout ratio is currently 35.16%.

Insider Activity at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by company insiders.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms issued reminders and deadline notices tied to an ongoing securities fraud class action against Zoetis, alleging investors were harmed by false or misleading statements during the Jan. 14, 2025 to May 6, 2026 period. These headlines can weigh on sentiment because they raise legal overhang and potential financial/reputational risk.
• Negative Sentiment: Zoetis was reportedly downgraded after a steep broader market selloff, signaling weakening near-term sentiment from Wall Street and adding to pressure on the stock.
• Negative Sentiment: A bearish article highlighted lawsuits challenging the company’s companion-animal outlook, suggesting investors may be questioning growth assumptions for a key business segment.
• Neutral Sentiment: Zoetis presented at the 46th Annual William Blair Growth Stock Conference, which may help investors gauge management’s outlook and strategy, but no major new catalyst was highlighted in the transcript headline.
• Neutral Sentiment: One valuation-oriented piece argued Zoetis could be a deep-value opportunity with significant upside, which may support longer-term sentiment but is unlikely to outweigh today’s legal and rating-related headlines.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. BTIG Research reiterated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Finally, Citigroup lowered their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average target price of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.